Journal of Genetic Syndromes & Gene Therapy
Open Access

Ion transport defects in Microvillus Inclusion Disease (MVID)

2^nd World Congress on Rare Diseases and Orphan Drugs

June 29-30, 2017 London, UK

Nadia Ameen

Yale University School of Medicine, USA

Scientific Tracks Abstracts: J Genet Syndr Gene Ther

Abstract :

MVID is a rare congenital disease that results in severe secretory diarrhea (SD) and death in newborns. B rush border (BB) defects, villus atrophy and microvillus inclusions (MVIs) in enterocytes are associated with the diarrrhea. Loss of function mutations in the actin motor Myosin Vb (Myo5b) is responsible for most cases of MVID. How loss of Myo5b results in secretory diarrhea is unknown. The study used Myo5b loss of function human MVID intestine, polarized intestinal cell models of secretory crypt (T84) and villus resembling (C2BBe) enterocytes lacking Myo5b in conjunction with immunofluorescence confocal gSTED imaging, immunohistochemical staining, TEM, shRNA silencing, immunoblots, and electrophysiologic approaches to examine the distribution, expression and function of the major BB ion transporters (Na+ (NHE3), Cl- (CFTR) and Cl-/HCO3- (SLC26A3, DRA), that control intestinal fluid transport. NHE3 and DRA localization and function were markedly reduced on the BBM of human MVID enterocytes and Myo5bKD C2BBe cells, while CFTR localization was preserved. Forskolin-stimulated CFTR ion transport in Myo5bKD T84 cells resembled that of control. Preservation of functional CFTR in immature enterocytes, reduced functional expression of NHE3 and DRA contribute to Cl- and Na+ stool loss in MVID diarrhea.

Biography :

Nadia Ameen completed her Medical Degree from the University of the West Indies, Jamaica. She completed training in Pediatrics at Children’s Hospital Wisconsin and then pursued Post-doctoral fellowship in Gastroenterology at Yale University School of Medicine. She is the Principal Investigator of an NIH supported research laboratory at Yale University, and studied CFTR and diarrheal diseases for over 20 years. She was the first to recognize a trafficking defect in MVID before a genetic defect was identified. She has authored more than 30 papers in reputed journals and serves as an Editorial Board Member for several journals.

Email: nadia.ameen@yale.edu